Company Name: |
Jinan Good Medical &Technology Ltd Co., Gold
|
Tel: |
+86-0086-531-55562571,18953105926 +86-13553167512 |
Email: |
935170726@qq.com |
Products Intro: |
Product Name:T9175;A51 CAS:2079068-74-7 Purity:99 Package:100g
|
|
| Casein Kinase inhibitor A51 Basic information |
Product Name: | Casein Kinase inhibitor A51 | Synonyms: | Casein Kinase inhibitor A51;CKIα inhibitor A51;BTX-A51;1,4-Cyclohexanediamine, N1-[5-chloro-4-[5-(cyclopropylmethyl)-1-methyl-1H-pyrazol-4-yl]-2-pyrimidinyl]-, trans-;T9175;BTX-A51 (Casein Kinase inhibitor A51) | CAS: | 2079068-74-7 | MF: | C18H25ClN6 | MW: | 360.88 | EINECS: | | Product Categories: | | Mol File: | 2079068-74-7.mol | ![Casein Kinase inhibitor A51 Structure](CAS/20210305/GIF/2079068-74-7.gif) |
| Casein Kinase inhibitor A51 Chemical Properties |
Boiling point | 570.0±60.0 °C(Predicted) | density | 1.48±0.1 g/cm3(Predicted) | storage temp. | Store at -20°C | pka | 10.41±0.70(Predicted) | form | Solid | color | Off-white to brown |
| Casein Kinase inhibitor A51 Usage And Synthesis |
Biological Activity | Casein Kinase inhibitor A51 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A51 induces leukemia cell apoptosis, and has potent anti-leukemic activities[1].
Similar to CKIα depletion, Casein Kinase inhibitor A51 (0.05-3.2 μM; 18 hours) treatment of RKO cells abolished most of the Ser45 phosphorylation signal and the consecutive GSK3 phosphorylation cascade resulting in stabilization of β-catenin[1]. Casein Kinase inhibitor A51 is highly effective in inducing leukemia cell apoptosis at 160 nM or lower, mostly in correlation to their capacity to stabilize p53[1].Casein Kinase inhibitor A51 (0.08-2 μM; 6.5 hours) abolishes the expression of MYC, MDM2, and the anti-apoptotic oncogene MCL1. Casein Kinase inhibitor A51 induces a marked reduction in mRNA expression of MYC and MDM2, yet upregulates the expression of the Wnt targets AXIN2 and CCND1 (Cyclin D1)[1].
Oral treatment is initiated at 8 days (Casein Kinase inhibitor A51; 5 mg/kg/day) after leukemia cell inoculation, at which the percentage of leukemia cells in the BM is more than 1.5% of all cells. all A51-treated mice have normal organ morphology and histology and normal blood counts[1].Pharmacokinetic studies of the inhibitor Casein Kinase inhibitor A51 at 20 mg/kg reveal rapid oral absorption with a Tmax of 0.5-2 hr, Cmax of 1060 ng/mL, T1/2 of 2.5 hr, and area under the curve (AUC) values of 3680 (ng*hr/mL)[1]. | References | [1]. Waleed Minzel, et al. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018 Sep 20;175(1):171-185.e25. |
| Casein Kinase inhibitor A51 Preparation Products And Raw materials |
|